• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Emergent BioSolutions

    PCI Pharma Services

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Cytovance Biologics

    Adare Pharma Solutions

    Reed-Lane

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Chad Landmon, Michelle Divelbiss, and Alex Alfano of Axinn, Veltrop & Harkrider LLP
    Related CONTENT
    • Strata Oncology Unveils Strata PATH Trial
    • Phlow Corp. and USP Form Alliance
    • Cryoport Launches ESG Program
    • Solid Dose Market Trends
    • Manufacturing Equipment Trends
    Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups01.05.21
    The United States Food and Drug Administration (FDA) focuses on implementing and following procedures to ensure that the products it regulates are safe and effective.  As many in the regulated industries can attest to, sometimes disruptions occur.  Nevertheless, no one could have predicted the disruption brought by the COVID-19 virus in 2020.  This article will explore some areas in which FDA’s procedures were disrupted in 2020 and what the “new normal” might look like in 2021.

    Emergency Use Authorizations

    Before 2020, emergency use authorizations (“EUAs”) from FDA were familiar only to “FDA nerds.”  Now, EUAs are at the forefront of the daily news and were the topic of discussion at nearly every Zoom Thanksgiving dinner. 

    EUA Standards and Approvals

    The Federal Food, Drug, and Cosmetic Act (“FD&C Act”) permits emergency use of a product that “is not approved, licensed, or cleared for commercial distribution” or that is approved but the proposed use is not approved.[1]  For an emergency to exist and permit FDA to issue EUAs, the Secretary of the Department of Health and Human Services (“HHS”) must determine that there is “a public health emergency, or a significant potential to affect, national security or the health and security of United States citizens living abroad, and that involves a [chemical, biological, radiological, or nuclear] agent or agents, or a disease or condition that may be attributable to such agent(s),” which includes emerging infectious diseases.[2]  The FDA Commissioner may then permit EUAs within the scope of the declared emergency. 

    With novel and rapidly changing threats, FDA has some flexibility in authorizing EUAs.  EUAs for unapproved product uses are analyzed “based on the totality of scientific evidence available.”[3]  Using the evidence FDA has available, FDA may grant an EUA if “it is reasonable to believe that the product may be effective for the specified use.”[4]  FDA looks at a “may be effective” standard for EUAs, but with a non-emergency, routine approval FDA will look at a product’s “effectiveness,” which is a more exacting standard.[5]

    With the COVID-19 pandemic, EUAs focused not only on treatment, but also on supporting equipment, including personal protective equipment (“PPE”), ventilators, and diagnostics.  With a novel virus, the immediate focus was on prevention, causing a scramble for PPE.  For example, in March 2020, FDA addressed which filtering facepiece respirators, i.e., masks, are authorized to be decontaminated and reused by medical staff, requiring that the decontamination process have its own EUA.[6]  Even with an ongoing shortage of PPE, attention turned to supportive care, and FDA created the Coronavirus Treatment Acceleration Program (“CTAP”).  With CTAP, FDA is able to track new treatments, including the use of antivirals, cell and gene therapies, immunomodulators, neutralizing antibodies, and many other treatments.[7]

    As we have seen in the last few weeks, FDA has begun reviewing clinical studies and data to support EUAs for vaccines.  Although the vaccines have been developed at breakneck speed, the clinical trials have enrolled tens of thousands of study participants in order to obtain the data needed for EUA or eventual full approval.  On December 11, 2020, FDA granted Pfizer’s vaccine authorization for emergency use.  Pfizer’s “late-stage clinical trial, which enrolled nearly 44,000 people, was . . . 95 percent effective,”[8] and FDA’s approval demonstrates that “the known and potential benefits outweigh the known and potential risks of the vaccine.”[9] 

    Unavoidable Pitfalls of EUA

    FDA’s work during this national health crisis has been extraordinary, but that is not to say that everything has been perfect.  Though critics might say that “fast is the enemy of good,” that is somewhat misleading; FDA makes the best decisions it can with the information it has available. 

    Facing immense pressure, on March 28, 2020, FDA granted an EUA for chloroquine phosphate and hydroxychloroquine sulfate to treat patients with COVID-19 “based on the science and data available at the time.”[10]  With its ongoing review of the most up-to-date data and clinical experience, however, on June 15, 2020, FDA revoked that EUA “in light of ongoing serious cardiac adverse events and other potential serious side effects,” finding that the potential treatment benefits “no longer outweigh the known and potential risks for the authorized use.”[11]

    Our constantly changing body of knowledge about this novel virus is not limited to treatments.  Many diagnostic tests were granted EUAs at the beginning of 2020 in the hope of identifying infected individuals to slow the spread of the virus.  With some of these diagnostic tests, the Abbott ID NOW point-of-care test for example, early data suggests that these tests returned many false negative results.[12]  Particularly with a rapidly spreading and contagious virus, false negative tests can result in patients who think they are not contagious but are unknowingly infecting others.  Unfortunately, public confidence in FDA’s response to the pandemic took a bit of a hit with this, and FDA continues to face the difficult task of revoking EUAs when data suggests that the benefits no longer outweigh the risks.

    Despite some speedbumps along the way, however, FDA has worked with industry to address these problems as they arise.  As Abbott’s point-of-care test has demonstrated, rigorously collecting data and analyzing it is key to having the most up to date understanding of this virus.  FDA has partnered with various companies and organizations, including Aetion,[13] the Critical Path Institute, and the National Center for Advancing Translational Sciences,[14] to focus on data collection and analysis. 

    Operation Warp Speed

    In a push to move treatments towards an EUA, Operation Warp Speed was established as a collaboration between the Department of Health and Human Services (HHS) and the Department of Defense.[15]  With Operation Warp Speed, a vaccine’s path to development is essentially the same, but components proceed simultaneously instead of step-wise.[16]  Additionally, the U.S. government would lend support to private companies and would oversee the clinical trial protocols.[17]

    One of the ways that the government has provided substantial support is with involvement of the U.S. military.  We have seen how this pandemic has strained even the most robust supply chains, and that has been an ongoing concern for PPE, therapeutics, and other products such as needles and vials.  But for a vaccine to succeed, manufacturers needed to ensure they had all of the supplies ready to be able to distribute the vaccine once approved.  Here, for example, the military aided the vaccine manufacturers by ensuring they have all of the raw materials needed.[18] 

    By all accounts, this operation was a success.  On December 11, 2020, about 10 months after the first recorded death from COVID-19 in the U.S., FDA issued an EUA for the first COVID-19 vaccine.[19]  Only a few days later, on December 14, the first individuals in the U.S. were given the vaccine.[20]  This worldwide pandemic has demonstrated that the government has the ability to pair its regulatory function (and sometimes financial resources) with industry’s infrastructure and R&D capabilities to lead to the development and approval of medical vaccines and therapies at an incredibly fast pace.  Going forward, these partnerships will be key to mitigating and solving healthcare crises as they occur.  Still, this success was not without setbacks, most notably the appearance of politicization of the FDA.

    Political Pressure

    Although FDA functions within HHS, which is part of the executive branch, FDA’s focus is on science, not politics.  FDA’s integrity is bolstered by three criteria: (1) “decisions should be based on a rigorous evaluation of the best available science, drawing on appropriate expertise, including the use of advisory committees”; (2) “decisions should be reached and documented through a process that promotes open-mindedness, with the bases of final decisions and processes for decision-making . . . adequately documented and explained”; and (3) “decisions should be made without inappropriate or external interference.”[21] 

    As the current pandemic has thrown FDA and its decision-making into the spotlight, it is likely that as the crisis abates (even slightly), FDA will turn to these criteria more deliberately and publicly.  With additional transparency guided by these principles, FDA can garner confidence in its independence; this confidence will also be key to ensuring that an adequate number of individuals get a COVID-19 vaccine. 

    FDA’s Use of Real-World Evidence and Future Advancements

    As discussed with respect to EUAs, FDA has been using real-world evidence (“RWE”) to monitor and update its current thinking about a particular product or therapy.  The COVID-19 pandemic has shown FDA and industry just how important immediate, up-to-date data is to prevent the spread of the virus and to ease the burden on health care professionals.  In fighting this pandemic, not only do local and national government entities need to understand the effectiveness of certain devices or therapies, these entities also can use telemedicine or patient monitoring devices to get a more accurate view of disease progression and spread.

    Most products approved by FDA have some post-approval monitoring, whether it is through a post-market safety study or reporting.[22]  In recent years, FDA has launched the Sentinel Initiative, which comprises a database focused on the safety of medical products.[23]  This initiative uses RWE, which has “eliminated the need for postmarketing studies on nine potential safety issues involving five products.”[24]  FDA acknowledges that using RWE can allow FDA “to provide patients and providers with important answers sooner – identifying a broader range of safety signals and following up on them more efficiently.”[25] 

    With one vaccine already granted an EUA and more EUAs likely on the way, FDA has established a system using RWE to evaluate ongoing vaccine safety as the vaccines are distributed across the country.  Dr. Moncef Slaoui, who is on the Operation Warp Speed panel, stated that the panel is “working with the FDA and CDC to set up together a very, very high performance, active pharmacovigilance system that resembles almost to the day the assessment that we do in clinical trials to look at the safety of the vaccines in the population . . . .”[26]  Not only will the data collection be robust, “these data will be analyzed on a [day-by-day] basis.”[27]

    The day-to-day analysis of vaccine safety data might be a signal that FDA is more willing to expand its use of RWE and/or telemedicine to track efficacy and safety outcomes.  For example, FDA has stated that “[s]oon, the FDA will have more to say in guidance about how to interpret [FDA’s] evidentiary standard in the context of today’s modern informatics and advanced analytics, which provide new openings for the collection of data and the generation of evidence.”[28]  Additionally, FDA has issued guidance regarding remote monitoring devices used to support patients during the pandemic.[29]  At least during this public health emergency, “FDA does not intend to object to limited modifications . . . [to] certain non-invasive remote monitoring devices.”[30]  Here, for example, modifications such as “[h]ardware or software changes to allow for increased remote monitoring capability,” will be permitted even without a 510(k) premarket notification.[31]

    If this commitment to using RWE and expanding the use of telemedicine continues after the conclusion of the pandemic emergency, it would provide a huge advantage by having FDA’s decisions reflect current data and analyses, instead of sometimes being constrained by delays in data aggregation and analysis.

    2021:  a slow return to “normalcy”

    When the calendar turns to January 1, 2021, we will be hoping for a fresh start and a more hopeful outlook.  FDA will still be focused on addressing many pandemic-related issues, but there will eventually be a shift back to quasi-normalcy.  It is unclear whether FDA (or anyone for that matter) will return to a pre-pandemic normal, but we might start seeing FDA’s focus shift to more normal operations and its core mission. 

    Given that FDA’s focus in 2020 was understandably dominated by its COVID response, large numbers of FDA personnel were taken away from their typical day-to-day activities.  As we settle into the “new normal,” those personnel will eventually be able to return to their usual functions.  Of course, we can expect to see the lessons learned during COVID—and many of the practices that were embraced by necessity—come to have a more lasting impact on how FDA and the regulated industries conduct business.  And, as we look back to evaluate the successes and missteps of the past year, FDA will undoubtedly adjust its strategic plans in preparation for any future pandemics.   

    Even as COVID no longer dominates our dinner conversations, the lessons learned will serve us for decades to come.  FDA will be able to analyze mountains of data to determine which actions were successful and which need improvement.  If we encounter another pandemic—a scenario that is not unlikely—FDA will be able to improve and more swiftly tackle the pressing issues.  As we round the corner to 2021, we should look to the future with renewed confidence in both FDA and in our own abilities to confront the unknown.


    [1] 21 U.S.C. § 360bbb-3(a)(2).
    [2] Emergency Use Authorization of Medical Products and Related Authorities, Guidance for Industry, at 5 (Jan. 2017), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities [hereinafter EUA Guidance].  The Secretary of Homeland Security or the Secretary of Defense may also declare an emergency under certain standards.
    [3] 21 U.S.C. § 360bbb-3(c)(2).
    [4] EUA Guidance, supra note 3, at 8.
    [5] Id.
    [6]
    See Coronavirus (COVID-19) Update: FDA Reissues Emergency Use Authorizations Revising Which Types of Respirators Can be Decontaminated for Reuse, FDA News Release (June 7, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-reissues-emergency-use-authorizations-revising-which-types; Letter from FDA to Manufacturers of Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators et al. (June 6, 2020), available at https://www.fda.gov/media/136403/download.
    [9] Emergency Use Authorization for Vaccines Explained, U.S. FDA, https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained.
    [10] Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine, FDA News Release (June 15, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
    [11] Id.; see Letter from FDA to Gary L. Disbrow Ph.D., Deputy Assistant Secretary, (June 15, 2020), available at https://www.fda.gov/media/138945/download.
    [12] See Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test, FDA News Release (May 14, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point.
    [13] See Coronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response, FDA Statement (May 19, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-collaborations-promote-rigorous-analyses-real-world-data-inform.
    [14] Innovation to Respond to COVID-19, U.S. FDA (July 16, 2020), https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/innovation-respond-covid-19.
    [15] See Fact Sheet: Explaining Operation Warp Speed, U.S. Dept. of Health and Human Services (last visited Dec. 17, 2020), https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html.
    [16] See id.
    [17] See id.; Operation Warp Speed: Vaccines, Diagnostics, and Therapeutics, Centers for Disease Control and Prevention (July 2, 2020), https://www.cdc.gov/washington/testimony/2020/t20200702.htm.
    [18] See Officials Optimistic About COVID-19 Vaccines in Near Future, U.S. Dept. of Defense (Nov. 18, 2020), https://www.defense.gov/Explore/News/Article/Article/2420190/officials-optimistic-about-covid-19-vaccines-in-near-future [hereinafter Officials Optimistic About COVID-19 Vaccines].
    [19] See FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine, FDA News Release (Dec. 11, 2020), https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19; First known U.S. coronavirus death occurred on Feb. 6 in Santa Clara County, S.F. Chronicle (Apr. 22, 2020), https://www.sfchronicle.com/health/article/First-known-U-S-coronavirus-death-occurred-on-15217316.php.
    [20] See First Covid-19 Vaccine Given to U.S. Public, The Wall Street Journal (Dec. 14, 2020), https://www.wsj.com/articles/covid-19-vaccinations-in-the-u-s-slated-to-begin-monday-11607941806.
    [21] How the FDA should protect its integrity from politics, Nature (Sept. 9, 2020), https://www.nature.com/articles/d41586-020-02542-8 (internal quotations omitted).
    [22] See Step 5: FDA Post-Market Drug Safety Monitoring, U.S. FDA, https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring.
    [23] See FDA’s Sentinel Initiative, U.S. FDA, https://www.fda.gov/safety/fdas-sentinel-initiative.
    [24] Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics, FDA Statement (Dec. 6, 2018), https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fdas-new-strategic-framework-advance-use-real-world [hereinafter FDA Real-World Evidence Statement].
    [25] Id.
    [26] Officials Optimistic About COVID-19 Vaccines, supra note 19.
    [27] Id.
    [28] FDA Real-World Evidence Statement, supra note 25.
    [29] See Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised), Guidance for Industry (Oct. 2020), available at https://www.fda.gov/media/136290/download.
    [30] Id. at 8.
    [31] Id.



    Chad Landmon chairs Axinn, Veltrop & Harkrider LLP’s Intellectual Property and Food and Drug Administration Practice Groups and focuses his practice on patent litigation and counseling and food and drug law, with an emphasis on pharmaceuticals, biologics, medical devices, and human tissue products. He maintains a particular focus on patent trial work and FDA litigation, having served as a first chair trial lawyer on multiple cases and having litigated over 50 cases during the past 10 years alone, many of which have included products with billions of dollars in annual sales.

    Michelle Divelbiss is an attorney in Axinn, Veltrop & Harkrider LLP’s Intellectual Property and Food and Drug Administration practice groups. Her practice involves patent litigation, particularly cases brought under the Hatch-Waxman Act, and counseling relating to FDA matters.






    Alex Alfano is an attorney in Axinn, Veltrop & Harkrider LLP’s Intellectual Property and Food and Drug Administration practice groups. His patent litigation practice focuses on biotechnology, pharmaceuticals, medical devices, diagnostics, and the life sciences. His experience includes pre-litigation client counseling, inter partes proceedings, cases brought under the Hatch-Waxman Act, and counseling relating to FDA matters.
    Related Searches
    • Drug Development
    Suggested For You
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    Cryoport Launches ESG Program Cryoport Launches ESG Program
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Anova Enterprises Acquires Corlexia Clinical Services Anova Enterprises Acquires Corlexia Clinical Services
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement
    UK Secures 40M Doses of Valneva COVID-19 Vax UK Secures 40M Doses of Valneva COVID-19 Vax

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20


    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20

    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20


    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20


    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20


    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    • cGMP Manufacture | Clinical Trials | Drug Development | Information Technology | R&D
      COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism

      COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism

      The rise of new tools and approaches, an increase in regulatory responsibility, and the need for speed.
      Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances 05.18.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login